Devanand

Acute Graft Versus Host Disease (GvHD) Treatment Market: Introduction According to the report, the global acute graft versus host disease treatment market was valued at US$ 263 Mn in 2020 and is projected to expand at a CAGR of 8.6% from 2021 to 2031. The rise in focus on introducing novel effective therapeutics to address the unmet medical needs is anticipated to drive the global acute graft versus host disease (GvHD) treatment market from 2021 to 2031. North America is expected to account for significant share of the global acute graft versus host disease (GvHD) treatment market during the forecast period. The growth of the acute graft versus host disease (GvHD) treatment market in the region can be attributed to the presence of key players and rise in access to health care due to well-established healthcare infrastructure. Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82607 The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2031. Emerging approached for mesenchymal stem cells (MSCs) to treat acute graft versus host disease (GvHD) in Japan is projected to boost the growth of market in the region. Focus on Research & Development to Propel Market The development of innovative and effective health products for humans has increased in the past few decades. Key players focus on introduction of new drugs in the market. The research-based pharmaceutical industry can play a critical role in restoring growth and ensuring future competitiveness in an advancing global economy. High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market. For instance, in July 2021, Equillium, Inc. announced the completion of an end-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) for use of itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82607 Corticosteroids to Dominate Global Market In terms of drug class, the global acute graft versus host disease (GvHD) treatment market has been classified into corticosteroids, immunosuppressive agents, biological therapy, kinase inhibitors, monoclonal antibody, mesenchymal stem cell (MSC), and others. First-line use of corticosteroids in the treatment of GvHD is likely to boost the growth of segment. Intravenous Segment to Expand at High Growth Rate Based on route of administration, the global acute graft versus host disease (GvHD) treatment market has been categorized into oral, topical, and intravenous. Increase in usage and launch of new injectable drugs for treatment of acute graft versus host disease are projected to augment the segment during the forecast period. Request Customization on Acute Graft Versus Host Disease Treatment Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=82607 Retail Pharmacies to Account for Major Share of Global Market In terms of distribution channel, the global acute graft versus host disease (GvHD) treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The increase in the number of different doses and medications for the treatment of acute GvHD is anticipated to drive the retail pharmacies segment. Competition Landscape of Acute Graft Versus Host Disease (GvHD) Treatment Market The report provides profiles of leading players operating in the global acute graft versus host disease (GvHD) treatment market. These include Bristol-Myers Squibb, Novartis AG, Mesoblast Ltd, Equillium, Inc., Cynata Therapeutics Limited, MaaT Pharma, Incyte Corporation, Xenikos B.V., Merck & Co. (OncoImmune, Inc.), medac GmbH, and CSL Limited. Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=82607 Global Acute Graft Versus Host Disease (GvHD) Treatment Market: Segmentation Acute Graft Versus Host Disease (GvHD) Treatment Market, by Drug Class Corticosteroids Immunosuppressive Agents Biological Therapy Kinase Inhibitors Monoclonal Antibody Mesenchymal Stem Cell (MSC) Others Acute Graft Versus Host Disease (GvHD) Treatment Market, by Route of Administration Oral Topical Intravenous Acute Graft Versus Host Disease (GvHD) Treatment Market, by Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies About Us Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact Us Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/  

 Traditional Chinese Medicine for Skincare Market: Introduction According to the report, the global traditional Chinese medicine for skincare market was valued at US$ 3.5 Bn in 2019 and is projected to expand at a CAGR of ~8% from 2020 to 2030. Traditional Chinese medicinal system is one of the oldest Chinese medicinal systems with focus on entire body’s well-being. Traditional Chinese medicinal system is based on balance, harmony, and energy. Different types of traditional Chinese medicine are used in the treatment of skincare problems such as eczema, acne, hypopigmentation, psoriasis, and others. The growth of the global traditional Chinese medicine for skincare market can be ascribed to the entry of pharmaceutical companies in the market and rise in popularity of traditional Chinese ingredients. Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81414 Asia Pacific dominated the global traditional Chinese medicine for skincare market in 2019. The trend is anticipated to continue during the forecast period. Presence of major players, significant healthcare expenditure, early availability of new products, and increase in export of traditional Chinese medicine drive the market in Asia Pacific. Additionally, large patient base in countries such as India, Japan, and China and rise in the number of traditional Chinese medicine for skincare service providers drive the market in the country. North America is projected to be the second largest market for traditional Chinese medicine for skincare during the forecast period. It is likely to expand at a high CAGR during the forecast period. Entry of Pharmaceutical Companies and Popularity of Traditional Chinese Ingredients to Drive Global Market Pharmaceutical firms in China that treat TCM products are gradually entering the cosmetics market. This can be attributed to the consistent rise in the prices of fresh herbal medicinal ingredients, which makes it difficult to hold the cost of TCM products down, prompting these pharmaceutical firms to pursue a new source of revenue. The growing popularity of traditional Chinese ingredients due to increase in household income of customers in China is creating a major market for natural skincare goods, as consumers are willing to pay a premium to avail the advantages of organic beauty products. Request COVID Analysis on Traditional Chinese Medicine for Skincare Market –https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81414 Chinese Herbal Medicine to Dominate Global Market In terms of product type, the global traditional Chinese medicine for skincare market has been classified into Chinese herbal medicine, acupuncture, and diet therapy. The Chinese herbal medicine segment has been split into bodycare, face care, and foot & hand care. The Chinese herbal medicine segment dominated the global traditional Chinese medicine for skincare market in 2019 and the trend is likely to continue during the forecast period. Chinese herbal medicines are most commonly used in the treatment of skin disorders. Rise in prices and growing popularity of traditional Chinese medicine (TCM) have increased supply and demand for TCM. These factors are projected to fuel the growth of the segment during the forecast period. Acupuncture was the second largest segment in terms of market share in 2019. The growth of the segment can be attributed to increase in its use to relieve pain and other skin problems. Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=81414 Acne to be Key Application Area of Traditional Chinese Medicine Based on application, the global traditional Chinese medicine for skincare market has been categorized into eczema, psoriasis, acne, hyperpigmentation, and others. The acne segment accounted for a prominent share of the global traditional Chinese medicine for skincare market in 2019. Acne is a common skin condition. The increase in incidence of acne is anticipated to drive the segment over the next few years. Acne affects nearly 50 million people in the U.S. each year. The increase in demand for traditional Chinese medicine for acne treatment is expected to propel the segment during the forecast period. Asia Pacific to Dominate Traditional Chinese Medicine for Skincare Market In terms of region, the global traditional Chinese medicine for skincare market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific dominated the global traditional Chinese medicine for skincare market in 2019, followed by North America. Asia Pacific’s large market share can be ascribed to acne, which is a common skin condition. The increase in incidence of acne is likely to drive the segment over the next few years. The traditional Chinese medicine for skincare market in North America is anticipated to expand at a significant CAGR from 2020 to 2030. Acne affects nearly 50 million people in the U.S. each year. The rise in demand for traditional Chinese medicine for acne treatment is projected to propel the segment during the forecast period. Competition Landscape of Traditional Chinese Medicine for Skincare Market The global traditional Chinese medicine for skincare market is fragmented in terms of the number of players. Key players operating in the global market include Shen-Nong Limited (Integrated Chinese Medicine Holding Ltd), Jahwa, Solstice Medicine Company, Inc., Yuannan Baiyao, The Mentholatum Company, and Eu Yan Sang. About Us Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact Us Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/  

Transparency Market Research (TMR) has published a new report titled, ‘Hospital acquired disease testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global hospital acquired disease testing market was valued at US$ 798.6 Mn in 2018 and is projected to expand at a CAGR of 14.7% from 2019 to 2027. Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1759 Overview Hospital acquired disease testing is used by health care professionals, especially by clinical laboratory technicians, for the diagnosis of nosocomial infection. The hospital acquired infection testing market has experienced strong growth in the last decade due to factors such as increased awareness about growth in the incidence of nosocomial infections globally and development of the innovative prevention and treatment solutions. Increase in Prevalence of Hospital Acquired Infections to Drive Market Demand for hospital acquired infection testing has increased due to high prevalence of hospital acquired infection globally. Therefore, several hospitals are focusing on expanding their in-house test menu. Without an active and widespread surveillance, identification of cultures of colonized nosocomial microorganisms would yield poor results. Better surveillance cultures enable the detection of unrecognized pathogen colonized patients and also assist in prevention of transmission of infections. Countries in Europe such as the Netherlands, Finland, and Denmark with active surveillance systems for nosocomial infection detection have been successful in controlling hospital acquired infection caused by pathogens such as MRSA, thereby stabilizing resistance rates. Request COVID Analysis on Hospital acquired disease testing Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1759 Urinary Tract Infection Segment to Dominate Market Based on test type, the global hospital acquired disease testing market has been divided into urinary tract, surgical site, pneumonia, bloodstream, MRSA, and others. Urinary tract infection is one of the most common infections with the highest prevalence globally, followed by surgical site infections. Other infections include respiratory, gastrointestinal, cardiovascular, bone, and joint-related infections. The global hospital acquired disease testing market is expanding at a promising rate owing to increasing prevalence of hospital-acquired infections, growing number of drug-resistant pathogens, and rising awareness among people regarding hospital-acquired diseases However, stringent regulations, guidance framework, and lack of budget and skilled labor in developing countries are expected to restrict the market growth during the forecast period Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1759 North America to Dominate Global Market Geographically, the global hospital acquired infection testing market has been segmented into North America, Europe, Asia Pacific, and Middle East & Africa. North America led the largest market share in 2018. It was followed by Europe in the same year. The hospital acquired infection market in Europe is mature due to presence of strong and active nosocomial infection control and prevention authorities and guidelines such as the NHS in the U.K. Asia Pacific is a lucrative market for hospital acquired infection testing products as the overall prevalence of nosocomial infections in this region is high. Moreover, stringent guidelines have been set for the prevention and control of such conditions in the health care infrastructure in this region. Countries such as China, India, Japan, Thailand, Australia, and the Philippines are expected to be the major contributors to the hospital acquired infection testing market in Asia Pacific. Competitive Landscape The hospital acquired disease testing market is highly fragmented with a number of international and local players operating in the market. The companies profiled in the report include Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., and Thermo Fisher Scientific, Inc. About Us Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact Us Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/  

Congenital Heart Disease Treatment Market: Introduction Congenital heart disease is a structural heart issue existing at the time of birth. It is one of the most common types of birth defects across the globe. In congenital heart disease, structure of the heart is developed abnormally. This includes defective heart valves, weak heart valves, and poor thickness of the heart arteries and veins. The abnormal heart structure leads to several complications such as low blood flow through the heart, blood flow in a wrong direction, and blockage of blood flow. Congenital heart disease can be diagnosed through physical examination and special heart tests. It can also be diagnosed during pregnancy. Common symptoms of congenital heart disease include poor blood circulation, rapid breathing, cyanosis, and fatigue. Most patients with the congenital heart disease show very less or no symptoms at early stages of the disease. The treatment of congenital heart disease includes use of drugs, catheter procedure, surgery, and heart transplant Read Report Overview: https://www.transparencymarketresearch.com/congenital-heart-disease-treatment-market.html Global Congenital Heart Disease Treatment Market: Key Drivers The global congenital heart disease treatment market is primarily driven by rise in the rate of incidence of congenital heart disease and launch of new products across the globe. The Centers for Disease Control and Prevention (CDC) estimates that one million children and one million adults in the U.S. are living with congenital heart disease currently. Also, advancements in early diagnosis of congenital heart disease and availability of new therapeutic drugs are likely to fuel the global congenital heart disease treatment market during the forecast period The family history of congenital heart disease and presence of underlying medical conditions, such as rubella, Type-1 diabetes, and Type-2 diabetes, during pregnancy increase chances of developing congenital heart disease in babies Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75169 ACE Inhibitors Segment to Dominate Global Market Based on drug class, the global congenital heart disease treatment market can be divided into angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers, antiarrhythmics, anticoagulants, antiplatelets, beta blockers, bosentan, digoxin, diuretics, sildenafil, and warfarin. The ACE inhibitors segment is anticipated to dominate the global market during the forecast period. ACE inhibitors are most commonly used for the treatment of high blood pressure and congestive heart failure. The most commonly prescribed ACE inhibitors are captopril, enalapril, lisinopril, ramipril, and trandolapril. Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75169 Retail Pharmacy Segment to Dominate Global Market In terms of distribution channel, the global congenital heart disease treatment market can be segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment is projected to dominate the global congenital heart disease treatment market during the forecast period. Easy availability of drugs for the treatment of congenital heart disease at retail pharmacy stores, presence of a large number of retail pharmacy stores across the globe, and rapidly growing number of retail pharmacy chains are factors responsible for the leading share of the retail pharmacy segment Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=75169 Congenital Heart Disease Treatment Market in Asia Pacific to Expand Rapidly In terms of region, the global congenital heart disease treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global market during the forecast period. However, the region is anticipated to lose market share by 2027. High prevalence of congenital heart disease among people in the U.S., technological advancements in early diagnosis of the disease, and increase in awareness about congenital heart disease in the region are projected to drive the market in North America from 2019 to 2027 The congenital heart disease treatment market in Asia Pacific is projected to expand at a high CAGR during the forecast period, owing to rapid increase in the number of patients with congenital heart disease, high prevalence of diabetes in densely populated countries such as India, China, and South Korea, and rapidly improving health care infrastructure in the region Key Players Operating in Global Market The global congenital heart disease treatment market is highly fragmented, with a large number of global players accounting for a major share of the market in respective regions. Key players operating in the global congenital heart disease treatment market are: Novartis AG Bayer AG Merck & Co. Inc. Johnson & Johnson Pfizer Inc. Amgen Inc. Bristol-Myers Squibb Company Abbott Orion Corporation Cardiorentis Ag About Us Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.   Contact Us   Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/  

Analysts’ Viewpoint on ECG Devices Market Scenario High prevalence of cardiovascular diseases across the globe and launch of technologically advanced ECG equipment are expected to propel the global ECG devices market during the forecast period. Increase in geriatric population, rise in number of people adopting sedentary lifestyle, and growth in tobacco & alcohol consumption are also anticipated to augment the ECG devices market. Increase in focus on health care in developing countries is likely to offer immense opportunities to players operating in the global ECG devices market. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=61827 Overview of Global ECG Devices Market ECG device is generally used alongside other tests to help diagnose and monitor conditions affecting the heart. It is a painless, non-invasive source that helps diagnose many common heart-related issues. Increase in geriatric population, unhealthy diet, and obesity among various age groups are projected to propel the ECG devices market in the near future. Rise in Prevalence of Cardiovascular Diseases across Globe to Drive Market The prevalence of cardiovascular diseases is high across the globe. Cardiovascular diseases include a group of disorders of blood vessels and the heart such as congenital heart disease, rheumatic heart disease, coronary heart disease, and cerebrovascular disease. Increase in prevalence of cardiovascular diseases in developing countries can be linked to the rise in incidence of hypertension; increase in smoking, and growth in obesity caused by sedentary lifestyle. Presence of a large patient pool suffering from cardiovascular diseases is projected to drive the global ECG devices market during the forecast period. Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=61827 Increase in Need for Cardiovascular Monitoring among Aging Population to Boost Market Aging is one of the key factors responsible for the increase in the incidence of disorders such as hypertension and high blood cholesterol level. This is likely to drive the demand for cardiovascular monitoring and diagnostic devices, such as ECG, that enable quick diagnosis of the disease and monitoring of patients. According to a study published in the American Journal of Medicine, the U.S. population is aging rapidly. Increase in life expectancy is likely to result in a doubling of the population aged 65 years or above from 40 million people in 2010 to 81 million by 2040. The mortality rate is the highest in Eastern Europe and middle-income countries. Overall CVD death rates are higher in low- and middle-income countries than those in developed countries. Increase in population aged 65 years or above augments the demand for diagnostic and monitoring devices including ECG devices. This is anticipated to drive the global ECG devices market during the forecast period. Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=61827 Growth in Demand for Resting ECG Procedures among Patients to Augment Market The resting ECG systems segment dominated the global ECG devices market, accounting for a market share of around 50% in 2021. Higher share of the segment can be ascribed to the better exchange of information through Cardiovascular Information Systems (CVIS) and Electronic Health Record (EHRs), which simplify ECG workflow and reduce the complexity associated with custom integration, and rise in usage of resting ECG systems in hospitals, clinics, and ambulatory surgical centers. Development and launch of technologically advanced electrocardiogram devices – recently developed ECG monitoring systems are designed to improve workflow and simplify operation – is expected to propel the segment during the forecast period. Holter monitoring system and stress ECG system are also rapidly growing segments based on technology type. ECG Devices Primarily Being Used in Hospitals to Drive Hospitals Segment Based on end-user, the hospitals segment is projected to account for dominant share of the global ECG devices market from 2022 to 2031. The ambulatory surgical centers segment is also anticipated to grow at a high CAGR from 2022 to 2031. Major share of the hospitals segment can be ascribed to the increase in usage of ECG devices in cardiac settings across hospitals, as an electrocardiogram is the most common diagnostic tool in the cardiac department. It is also the most frequently performed test in hospitals. Increase in preference for ambulatory surgical centers, as these are high-quality, cost-effective settings for cardiac patients and cardiovascular procedures, is expected to propel the ambulatory surgical centers segment during the forecast period. Regional Outlook of Global ECG Devices Market North America accounted for the prominent share of around 40% of the global ECG devices market in 2021. The market in the region is projected to expand at a CAGR of more than 6.9% from 2022 to 2031. GE Healthcare and Philips Healthcare have reported significantly high sales of medical devices, including ECG devices, from North America, followed by Europe. In terms of CAGR, Asia Pacific is likely to be the fastest-growing region of the global market by 2031. The market in the region is expected to grow at a CAGR of 8.2% during the forecast period owing to the large population in countries such as India and China, significant presence of geriatric population in Japan, and improving health care facilities. Additionally, untapped opportunities and rise in awareness about cardiovascular diseases are expected to drive the ECG devices market in the region during the forecast period. Analysis of Key Players in Global ECG Devices Market The global ECG devices market is consolidated, with a few key players accounting for a major share. Most companies are making significant investments in research & development activities. Expansion of product portfolios and mergers & acquisitions are the key strategies adopted by the players. Key players operating in the market include GE Healthcare, Nihon Kohden Corporation, Hill-Rom Holdings, Inc., Koninklijke Philips N.V., Spacelabs Healthcare (OSI Systems, Inc.), Fukuda Denshi Co., Ltd, SCHILLER AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and CompuMed, Inc.    

MicroRNA Market – Overview The global microRNA market is projected to witness notable growth during the forecast period set between 2021 and 2031. This is attributed to the increasing number of diseases that requires microRNA applications as a means for clinical study or therapeutic purpose. The key market factors forming the future incorporate arising microRNA apparatuses for fluctuated disease-related applications, the utilization of microRNA in forecast and distinguishing proof, and the likely candidate for biopharma organizations to foster future medicines. Biopharma firms across the globe, are occupied with growing new molecules as a potential drug candidate likewise driving the microRNA market development. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1515 The growing adoption of microRNA as a biomarker is a key factor driving the market. The miRNA biomarkers are of specific concentration in genome-wide investigations, information-driven methodology, as they show high reproducibility and power when contrasted with conventional strategies. Thus, they fill in as promising candidates for the improvement of biomarkers. Also, the developing interest in liquid biopsies has additionally prompted the expanding significance of miRNAs for biomarker disclosure and improvement. The report on the global microRNA market provides a comprehensive overview of the market and how can it derive benefits in the coming years. Additionally, the impact of the novel COVID19 pandemic prevalent on this market and the key strategies that can be adopted by players to gain benefit from this situation are also discussed in details in this report. Factors attributing to the growth or downfall of this market such as drivers, restraints, challenges, and upcoming growth opportunities are also listed in this report. Additionally, the report also provides the list of all players and their chief contributions to the market. Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1515 MicroRNA Market – Competitive Landscape Biopharmaceutical companies are progressively captivating in the quest for new remedial molecules that can go about as new drugs that are further driving the market for microRNA. There are a few miRNA-based candidates that are under clinical preliminaries, for example, hostile to miR mixtures and explicit inhibitors for miRNAs which can go about as likely remedial solutions. Henceforth, RNA therapeutics is viewed as a moving contributing region that will prompt the advancement of productive drugs. Some of the key players of the global microRNA market include: Biodynamics Laboratory Inc. Miltenyi Biotec BioGenex Quantabio GeneCopoeia Inc. Synlogic Thermo Fisher Scientific Inc. OriGene Technologies Inc. Sistemic Scotland Limited SwqMatic LLC NanoString New England Biolabs QIAGEN Horizon Discovery Ltd. Merck KGaA Other players Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1515 MicroRNA Market – List of Innovations Scinogy and Thermo Fisher Scientific entered into a strategic collaboration in May 2019 for accelerating various gene and cell therapy and microRNA therapy commercialization. The Medicines Company was acquired by Novartis in November 2019 for about USD 9.7 billion. The objective behind this massive collaboration is to add potential miRNA and siRNA first-in-class inhibitor and continue building pipeline depth in such therapeutics. MicroRNA Market – Growth Drivers The mechanical development for working on the responsiveness and selectivity of miRNA identification is further adding to the development of the market for microRNA. The recently evolved techniques for miRNA recognition incorporate nanoparticle-based amplification, RCA-based strategies, DSN-based strategies, LAMP-based strategies, and without enzyme amplification, that may further add in favor of the market competition. In January 2020, scientists fostered a program-based isothermal amplification strategy for explicit and quantitative advanced estimation of miRNA. The upside of the framework is that pollution is diminished by the way that this framework is subject to the sign amplification process instead of coordinating replication of the designated grouping, as it completes the utilization of PCR-based methodologies. MicroRNA Market – Regional Insights Geographically, the global microRNA market was dominated by North America on account of the presence of better research centers and highly efficient scientists specializing in the fields of oncology, genomics, proteomics, and others. For example, DiamiR got a U.S. Patent endorsement for miRNA-based techniques that are utilized for observing mind aging and discovery in May 2020. This patent covers the utilization of techniques for quantitative examination of miRNA present in discernible blood plasma and mind as biomarkers of cerebrum aging.  

3D Mammography Market: Introduction Breast tomosynthesis, also known as 3D mammography, is the latest technology used for breast cancer screening. According to Hologic, its Hologic 3Dimensions™ Mammography System detect 20%-65% more invasive cancer than 2D mammography systems. 3D mammography allows visualization in thin slices, as tomosynthesis eliminates overlap of normal tissue, thereby decreasing inaccurate readings Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74627 Key Drivers of Global 3D Mammography Market The global 3D mammography market is likely to be driven by the rise in prevalence of breast cancer. Incidences of breast cancer are higher in developed countries while mortality rate is higher in lesser-developed and poor countries due to late diagnosis and availability of necessary health care and treatment facilities. Therefore, rise in prevalence of breast cancer in developed and developing countries across the globe is anticipated to drive the global 3D mammography market. According to the Centers for Disease Control and Prevention (CDC), breast cancer is the most common type of cancer in women. In 2017, breast cancer accounted for 30% of all types of newly diagnosed cancer among women. Increase in breast cancer research activities is driving the demand for 3D mammography systems. Moreover, 3D mammography systems are used for breast research to acquire a comprehensive understanding. This, in turn, is contributing to the growth of the global 3D mammography market. There is a rise in trend of rental contract agreement of 3D mammography systems. Rental contract agreements allow end-users to pay a certain amount per 3D mammogram performed using 3D mammography systems installed free of cost by manufacturers. This helps low budget hospitals and diagnostic labs to adopt this advanced technology for breast imaging. Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74627 Public mammography screening has been introduced in several countries in recent years.  3D mammography systems are used in these public mammography screening programs to obtain maximum accuracy in detection of breast cancer. North America to Hold Significant Share of Global 3D Mammography Market North America was the leading market for 3D mammography systems in 2018 driven by the rise in the adoption of technologically advanced devices for breast imaging. Moreover, rise in prevalence of breast cancer in the geriatric population is expected to propel the market during the forecast period. Favorable reimbursement policies in the U.S. for mammography is anticipated to augment the market in the region during the forecast period. According to the American Cancer Society, nearly 252,710 new cases of cancer were diagnosed in the U.S. in 2017 and the incidence rate is expected to increase substantially over the next few years Asia Pacific is projected to be the fastest growing market for 3D mammography during the forecast period due to the improving health care infrastructure. Rise in the number of diagnostic centers is likely to fuel the growth of the global 3D mammography market in Asia Pacific. Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=74627 Key Players Operating in Global 3D Mammography Market Major players in the global 3D mammography market are: General Electric Company Hologic, Inc. Siemens FUJIFILM Holdings America Corporation Konica Minolta, Inc. PLANMED OY  

Sports Medicine Devices Market: Introduction According to the report, the global sports medicine devices market was valued at US$ 9.08 Bn in 2020 and is projected to expand at a CAGR of 5.6% from 2021 to 2028. The sports medicine devices market is witnessing strong growth due to increase in demand for doctors, surgeons, nurses, physical therapists, and other healthcare professionals specialized in the field. This can be attributed to rise in unmet needs of providing effective treatment for various types of condition restricting the physical activities due to sports injuries. Increase in contact sports and exercise has created significant opportunities for people of all ages and physical abilities, races, and classes. Moreover, interest in professional sports and students participating in casual sports have increased in the last few decades. Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=765 The sports medicine devices market is characterized by minimally invasive arthroscopic procedures, which require less hospital stay and long-term effect. The recovery procedures not only concentrate on quick recovery from the injuries, but also have a continuous check to avoid any further damage to the injured joint or ligament. The global sports medicine devices market covers joint implants, fracture repair, arthroscopy devices, prosthesis, orthobiologics, and support & recovery products such as braces, bandages, tapes, hot/cold therapy products, and performance monitoring devices Rise in Awareness about Health Fitness Among Baby Boomers The global geriatric population has increased at a rapid rate in the past few years. This increase in the geriatric population and their rising interest toward fitness and exercise in an attempt to reduce cholesterol levels and control diabetes and obesity, and overall increased surge for life expectancy will significantly increase the use of medical devices. Majority of the elderly population engages in sports and fitness activities such as gym, yoga, and games including golf and cycling. Consequently, there have been incidences of dislocation of joints, trauma, fractures as well as ligament and meniscal injuries, requiring need of treatment, prevention, or rehabilitation with the use of sports medicine. Request for Covid-19 Impact Analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=765 Rise in Number of Sports Medicine Associations to Drive Market Sports medicine associations established across the globe contribute to the growth of the sports medicine devices market. These associations support various research activities in sports medicine, conduct various education programs, and also engage in providing fellowships for advanced education in sports medicine. Promotion of sports activities among the physically challenged is another important aspect of the developmental activities conducted by such associations. Arthroscopy Devices Segment Held Significant Market Share Arthroscopy is an endoscopic surgery used to treat a number joint injuries caused due to sports. The application of arthroscopy encompasses a range of sports injuries of shoulder, knee, foot, ankle, hip, elbow, and digits. Arthroscopy surgeries are a standard in treating anterior and posterior cruciate ligament of knee, rotator cuff tear of shoulder, and other cartilage, ligament, and tendon repair procedures. Athletes are always at a risk of acetabular labral tear due to rapid hip movements, sudden stop & turns, and extensive stretching. Labral tear causes pain in the groin and a sense of locking in the hip joint. Arthroscopic surgeries are performed to repair the cartilage if physiotherapy and other treatments have failed. Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=765 Advances in the imaging techniques such as HD and 3D HD coupled with bioabsorbable implants, knotless suture anchors, and fiber sutures have propelled the arthroscopy segment of the sports medicine devices market. Performance Monitoring Devices Segment to Lead Global Market Various vital signs are monitored and analyzed for surfacing the areas of improvement to observe the recovery of sports injuries. These devices include ECG monitors, pressure monitors, and heart rate monitors. New technology devices are portable and can be worn during the day to day activities, providing a continuous performance monitoring platform. Wearable ECG and heart rate monitors are widely used in sports and fitness areas where the sports trainers focus on stamina enhancement. Sensor insoles are used to analyze the pressure distribution and other dynamics of locomotion. Moticon manufactures sensor insoles, which measure weight distribution, balance, temperature, and acceleration. With the advent of smart phone applications and computer software suites, the market for sports performance monitors has expanded to non-professionals as well. These mobile phone applications are connected to monitoring devices through Bluetooth or Wi-Fi, and are more cost-effective than professional complex software suites. Dominance of Local Players Manufacturing Support & Recovery Products in Sports Medicines to Hamper Market Local manufacturers dominate the support & recovery segment, which includes braces, wraps, tapes, and hot & cold gel packs. These products are available at low cost compared to branded products. The local manufacturers save considerably on advertising and quality of products so that they can reduce the price and stay ahead in the competitive market. The product’s quality does not have a significant effect on the recovery, hence, non-professionals usually prefer inexpensive local products. Regional Analysis North America and Europe dominated the global market in 2020. However, the regions are projected to lose market share owing to strong market growth in Asia Pacific owing to economic development in emerging nations with high unmet medical needs. Asia Pacific is a lucrative market for these devices due to increase in sports injuries, rise in disposable income, surge in awareness about fitness among all generations in developing countries, increase in intensity of sports activities, and specialization of sports medicine included in latest educational courses. Competition Landscape of Sports Medicine Device Market The global sports medicine devices market is fragmented due to presence of large number of players. Key players operating in the global market include Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd., Graybug Vision, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited. About Us Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact Us Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/